Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sodium Stibogluconate in the Myelodysplastic Syndromes/Acute Myeloid Leukemia With One of the 65 Defined p53 Mutations That Can be Functionally Rescued by Sodium Stibogluconate

NCT04906031 is registered in ClinicalTrials.gov with First Affiliated Hospital of Jinan University as lead sponsor.

NCT NCT04906031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04906031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sodium Stibogluconate in the Myelodysplastic Syndromes/Acute Myeloid Leukemia With One of the 65 Defined p53 Mutations That Can be Functionally Rescued by Sodium Stibogluconate
Lead sponsor
First Affiliated Hospital of Jinan University
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2020
Completion date
February 1, 2024
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes, myeloid malignancy, p53 mutation, sodium stibogluconate, temperature-sensitive p53 mutation